Business Context and Reporting Period
Aptevo Therapeutics Inc. (APVO) filed a Form 8-K on May 25, 2026, reporting the entry into material definitive agreements with Niowave, Inc. The filing details a strategic collaboration to develop a human therapeutic product combining Aptevo's proprietary molecules (including APVO455) and Niowave's radioisotopes (including Actinium-225).
Key Financial Metrics and Transaction Details
This filing reports a specific capital raise and does not provide general financial statements (revenue, profit, or cash flow) for the period.
- Initial Investment: Niowave purchased 98,522 shares of common stock and warrants to purchase 53,201 shares.
- Purchase Price: Combined price of $5.075 per share, totaling approximately $500,000.
- Warrant Terms: Exercise price of $8.00 per share; expiration date of May 25, 2031.
- Future Funding Potential: Niowave has the option to purchase up to approximately 97,373 additional shares in future private placements at a predetermined price, subject to beneficial ownership limits (not exceeding 19.99%).
- Closing Date: The initial private placement closed on May 26, 2026.
Material Changes and Agreements
The primary material change is the execution of three concurrent agreements:
- Collaboration Agreement: Establishes a joint development program starting with a proof of concept study. Includes cross-licensing of background intellectual property.
- Supply Agreement: Provides for Niowave to supply radioisotopes to Aptevo if Niowave elects to opt-out of the development program at specific windows.
- Stock Purchase and Investor Rights Agreements: Facilitated the initial capital raise and granted Niowave registration rights and transfer restrictions.
Outlook, Risks, and Contingencies
Management highlighted several risks and contingencies associated with the transaction:
- Warrant Exercise Uncertainty: There is no assurance that Niowave will exercise the warrants for cash; they may expire unexercised or be exercised on a cashless basis.
- Ownership Limits: Warrant exercise is restricted if it causes Niowave to beneficially own more than 4.99% (or up to 9.99% at election) of outstanding common stock.
- Future Funding Contingency: Additional private placements are contingent on Niowave's election and regulatory milestones (e.g., IND approval) or the third anniversary of the agreement.
- Forward-Looking Statements: The filing disclaims obligations to update estimates regarding proceeds, timing, and completion of the private placements.
Investor Verification Checklist
- Verify the final closing conditions and actual proceeds received from the $500,000 Initial Niowave Private Placement.
- Review the full text of the Collaboration and Supply Agreements (to be filed as exhibits to the June 30, 2026, 10-Q) for specific opt-out windows and milestone definitions.
- Monitor the Company's capital structure to assess the dilution impact if Niowave exercises warrants or pursues additional private placements.
- Confirm the status of the proof of concept study and any regulatory filings related to the combination product.